These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12234610)

  • 21. Rapamycins: mechanism of action and cellular resistance.
    Huang S; Bjornsti MA; Houghton PJ
    Cancer Biol Ther; 2003; 2(3):222-32. PubMed ID: 12878853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis.
    Radisavljevic ZM; González-Flecha B
    J Cell Biochem; 2004 Apr; 91(6):1293-300. PubMed ID: 15048882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.
    Cao X; Kambe F; Moeller LC; Refetoff S; Seo H
    Mol Endocrinol; 2005 Jan; 19(1):102-12. PubMed ID: 15388791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacology of mTOR inhibition.
    Guertin DA; Sabatini DM
    Sci Signal; 2009 Apr; 2(67):pe24. PubMed ID: 19383975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway.
    Lee KW; Yook JY; Son MY; Kim MJ; Koo DB; Han YM; Cho YS
    Stem Cells Dev; 2010 Apr; 19(4):557-68. PubMed ID: 19642865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
    Hidalgo M; Rowinsky EK
    Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR.
    Lehman N; Ledford B; Di Fulvio M; Frondorf K; McPhail LC; Gomez-Cambronero J
    FASEB J; 2007 Apr; 21(4):1075-87. PubMed ID: 17242159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raptor and mTOR: subunits of a nutrient-sensitive complex.
    Kim DH; Sabatini DM
    Curr Top Microbiol Immunol; 2004; 279():259-70. PubMed ID: 14560962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
    Stylianou K; Petrakis I; Mavroeidi V; Stratakis S; Vardaki E; Perakis K; Stratigis S; Passam A; Papadogiorgaki E; Giannakakis K; Nakopoulou L; Daphnis E
    Nephrol Dial Transplant; 2011 Feb; 26(2):498-508. PubMed ID: 20709738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
    Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
    Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton.
    Sarbassov DD; Ali SM; Kim DH; Guertin DA; Latek RR; Erdjument-Bromage H; Tempst P; Sabatini DM
    Curr Biol; 2004 Jul; 14(14):1296-302. PubMed ID: 15268862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
    Tremblay F; Gagnon A; Veilleux A; Sorisky A; Marette A
    Endocrinology; 2005 Mar; 146(3):1328-37. PubMed ID: 15576463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ketamine administration on mTOR and reticulum stress signaling pathways in the brain after the infusion of rapamycin into prefrontal cortex.
    Abelaira HM; Réus GZ; Ignácio ZM; Dos Santos MA; de Moura AB; Matos D; Demo JP; da Silva JB; Michels M; Abatti M; Sonai B; Dal Pizzol F; Carvalho AF; Quevedo J
    J Psychiatr Res; 2017 Apr; 87():81-87. PubMed ID: 28017918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dissecting the role of mTOR: lessons from mTOR inhibitors.
    Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
    Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.